Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement-Reference-Cited by-同舟云学术

Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement

Published:2015-01-06 Issue:1 Volume:131 Page:62-73
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Garratt Kirk N.¹,Weaver W. Douglas¹,Jenkins Ronald G.¹,Pow Thomas K.¹,Mauri Laura¹,Kereiakes Dean J.¹,Winters Kenneth J.¹,Christen Thomas¹,Allocco Dominic J.¹,Lee David P.¹

Affiliation:

1. From Lenox Hill Hospital, New York, NY (K.N.G.); Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, MI (W.D.W.); Kootenai Medical Center, Coeur d’Alene, ID (R.G.J.); Lakeland Hospitals at St. Joseph, St. Joseph, MI (T.K.P.); Brigham and Women’s Hospital, Boston, MA (L.M.); The Christ Hospital Heart and Vascular Center/The Lindner Research Center Heart & Vascular Center, Cincinnati, OH (D.J.K.); Eli Lilly and Co, Indianapolis, IN (K.J.W.); Boston Scientific Corporation,...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference28 articles.

1. Propensity-Matched Patient-Level Comparison of the TAXUS Liberté and TAXUS Element (ION) Paclitaxel-Eluting Stents

2. Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions

3. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.;Mauri L;Am Heart J,2010

4. Dual antiplatelet therapy beyond one year after drug-eluting coronary stent procedures.;Mauri L;N Engl J Med

5. TCT-10 Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy;European Heart Journal - Cardiovascular Pharmacotherapy;2024-03-07

2. Performance of DAPT Score and ESC Criteria for Predicting Clinical Outcomes in Chinese Patients with Acute Coronary Syndrome;International Journal of General Medicine;2023-07

3. Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry;American Journal of Cardiovascular Drugs;2022-10-31

4. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management;Cardiovascular Diabetology;2022-05-14

5. In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches;Life;2022-03-08